Portfolio Finder

coramaze technologies GmbH, based in Munich, Germany and founded in 2013 as a University Hospital of Essen spin-off, is engaged in developing an innovative Mitral Valve repair system - mitramaze® - for a minimally invasive transcatheter repair of mitral regurgitation (MR).

Treatment of sustainable plaque in coronary arteries through our proprietary catheter based device.

Lymphatica Medtech develops medical devices for lymphatic disease treatment. The first product, LymphoDRAIN, is the worldwide first active lymphatic bypass for the treatment of chronic lymphedema, a disabling disease affecting millions of people worldwide.
Lymphatica developed its implantable drainage technology as a results of years of research at the Lausanne Federal Institute of Technology (EPFL) and of the Lausanne University Hospital (CHUV).

NovaPump GmbH is developing and realising a leading solution for a novel right ventricular assist device (RVAD) with clear USPs (the only percutaneous device with pulsatile support).
NovaPump’s catheter-based heart pump PERKAT™ can be implanted within minutes in acute situations involving acute right heart failure, cardiogenic shock or acute right heart insufficiency and offers highly efficient pulsatile heart support in combination with the existing IABP (Intra-Aortic Balloon Pump) technology as a drive.
A perspective application of PERKAT™ as a bi-ventricular assist device (bi-VAD) is also planned for the near future.

VACIS is the leading tissue engineering company for body-own blood vessels.
The VACIS technology uses a synthetic rod which induces the formation of a new fully functional blood vessel providing novel therapeutic options for vascular surgery. Prosthetic vascular graft failure is a frequent complication in vascular surgery with substantial morbidity and health care costs. VACIS provides patients autologous graft vessels, with sustained patency and fewer complications requiring less corrective interventions.
Vascular grafts are needed in many areas of medicine. VACIS initially focuses on vascular access in patients undergoing hemodialysis. Other indications will follow after clinical validation of the technology in hemodialysis. Such other indications include peripheral arterial occlusive disease.
VACIS provides an advantage over other therapeutic options in the hemodialysis access market. Current solutions have a low patency: many arteriovascular fistulas fail to mature or no adequate vein is available; the foreign material in synthetic grafts lead to infection, stenosis, thrombosis etc. and the synthetic material does not heal after cannulation.